CDT Equity Inc. (CDT) is a publicly traded company in the Healthcare — Biotechnology industry listed on NASDAQ. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
CDT Equity Inc., a data-driven biopharmaceutical company, focuses on identifying, enhancing, and monetising therapeutic assets. The company’s pipeline includes AZD1656, a glucokinase activator that is in Phase II trials for the treatment of autoimmune disorders, including uveitis, Hashimoto’s thyroiditis, preterm labor, and renal transplant; AZD5658, which is in Phase I clinical trial for the treatment of Type 2 Diabetes Mellitus; and AZD5904, which has completed Phase I clin...
Analysis Summary
Trailing-twelve-month margins: gross margin 38.7%, operating margin 11.6%, net margin 6.3%.
At the current price of $0.20, CDT trades at a P/E of 0.00 and an ROE of 9.26%. Market capitalisation stands at $0M.
Balance sheet quality for CDT: current ratio of 1.9, net debt of $895.8M. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Price
| Price | $0.20 |
| Market Cap | $0M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| P/E Ratio | 0.00 |
| Price / Book | 0.01 |
| EV / EBITDA | 3.99 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | 9.26% |
| Return on Invested Capital | 4.47% |
| Return on Assets | 2.60% |
| Gross Margin | 38.65% |
| Operating Margin | 11.55% |
| Net Margin | 6.30% |
Financial Health
| Debt / Equity | 0.95 |
| Current Ratio | 2.14 |
What to look at in Biotech
Most small biotechs lose money. Analysing them with P/E makes no sense — look at cash and pipeline.
- Cash Runway — Months of cash at current burn rate. <18 months = urgent dilution risk
- Annual cash burn — Rate at which they burn operating cash. Compare with cash position to project runway
- Total Debt — Biotech with no revenue + debt = recipe for bankruptcy
- R&D / Market cap — How much they invest in pipeline vs the company value — research-intensity indicator
- Market cap / Cash — If it trades near its cash, the market assigns ~0 value to the pipeline — opportunity or trap
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| CDT | CDT Equity Inc. | 0.00 | 0.01 | 9.3% | |
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $131.8B | |||
| VRTX | Vertex Pharmaceuticals Incorporated | $130.3B | 29.68 | 6.45 | 23.3% |
| 0R2M.L | Regeneron Pharmaceuticals, Inc. | $84.0B | |||
| REGN | Regeneron Pharmaceuticals, Inc. | $79.8B | 18.79 | 2.57 | 13.8% |
| ARGX | argenx SE | $61.2B | 36.30 | 7.40 | 21.7% |
| MRNA | Moderna, Inc. | $57.8B | 1.34 | -39.2% | |
| RVMD | Revolution Medicines, Inc. | $41.7B | 15.96 | -96.4% |
Price Performance
| 1 month | -93.15% |
| 3 months | -98.06% |
| Year-to-date | -99.94% |
| 1 year | -99.99% |
52-Week Range
| 52-week High | $2360.00 |
| 52-week Low | $0.18 |
| Avg Volume (90d) | 1.4M |
Related companies: CCM · COCH · ENVB · HEPA · LIXT · NIVF · PTPI
Explore sector: Healthcare · Biotechnology
More sections of CDT: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks